PDB Short entry for 2XHX HEADER CHAPERONE 21-JUN-10 2XHX TITLE STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND COMPND MOL_ID: 1; COMPND 2 MOLECULE: HEAT SHOCK PROTEIN HSP 90-ALPHA; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: N-TERMINAL DOMAIN (9-236); COMPND 5 SYNONYM: HSP 86, RENAL CARCINOMA ANTIGEN NY-REN-38; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: HSP90, HSP90A, HSP90AA1, HSPC1, HSPCA; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21(DE3) KEYWDS HSP90, CHAPERONE, ATP BINDING DOMAIN, N-TERMINAL DOMAIN, STRESS KEYWDS 2 RESPONSE EXPDTA X-RAY DIFFRACTION AUTHOR C.W.MURRAY,M.G.CARR,O.CALLAGHAN,G.CHESSARI,M.CONGREVE,S.COWAN, AUTHOR 2 J.E.COYLE,R.DOWNHAM,E.FIGUEROA,M.FREDERICKSON,B.GRAHAM,R.MCMENAMIN, AUTHOR 3 M.A.OBRIEN,S.PATEL,T.R.PHILLIPS,G.WILLIAMS,A.J.WOODHEAD, AUTHOR 4 A.J.A.WOOLFORD REVDAT 1 01-SEP-10 2XHX 0 JRNL AUTH C.W.MURRAY,M.G.CARR,O.CALLAGHAN,G.CHESSARI,M.CONGREVE, JRNL AUTH 2 S.COWAN,J.E.COYLE,R.DOWNHAM,E.FIGUEROA,M.FREDERICKSON, JRNL AUTH 3 B.GRAHAM,R.MCMENAMIN,M.A.O'BRIEN,S.PATEL,T.R.PHILLIPS, JRNL AUTH 4 G.WILLIAMS,A.J.WOODHEAD,A.J.A.WOOLFORD JRNL TITL FRAGMENT-BASED DRUG DISCOVERY APPLIED TO HSP90. DISCOVERY JRNL TITL 2 OF TWO LEAD SERIES WITH HIGH LIGAND EFFICIENCY. JRNL REF J.MED.CHEM. V. 53 5942 2010 JRNL REFN ISSN 0022-2623 JRNL PMID 20718493 JRNL DOI 10.1021/JM100059D REMARK 2 REMARK 2 RESOLUTION. 2.80 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.6.0062 REMARK 3 AUTHORS : MURSHUDOV,VAGIN,DODSON REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.801 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 48.80 REMARK 3 DATA CUTOFF (SIGMA(F)) : NONE REMARK 3 COMPLETENESS FOR RANGE (%) : 96.10 REMARK 3 NUMBER OF REFLECTIONS : 4356 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.25166 REMARK 3 R VALUE (WORKING SET) : 0.24383 REMARK 3 FREE R VALUE : 0.40685 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.9 REMARK 3 FREE R VALUE TEST SET COUNT : 223 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.801 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.874 REMARK 3 REFLECTION IN BIN (WORKING SET) : 319 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 97.38 REMARK 3 BIN R VALUE (WORKING SET) : 0.326 REMARK 3 BIN FREE R VALUE SET COUNT : 15 REMARK 3 BIN FREE R VALUE : 0.234 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1679 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 22 REMARK 3 SOLVENT ATOMS : 69 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 42.975 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 2.60 REMARK 3 B22 (A**2) : -4.30 REMARK 3 B33 (A**2) : 1.45 REMARK 3 B12 (A**2) : 0.00 REMARK 3 B13 (A**2) : -0.64 REMARK 3 B23 (A**2) : 0.00 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): NULL REMARK 3 ESU BASED ON FREE R VALUE (A): 0.749 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.604 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 57.195 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.925 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.784 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 1730 ; 0.012 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): 1172 ; 0.001 ; 0.020 REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 2337 ; 1.380 ; 1.955 REMARK 3 BOND ANGLES OTHERS (DEGREES): 2869 ; 0.909 ; 2.971 REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 212 ; 7.461 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 80 ;41.132 ;25.200 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 317 ;19.011 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 7 ;27.184 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 264 ; 0.072 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 1908 ; 0.004 ; 0.021 REMARK 3 GENERAL PLANES OTHERS (A): 334 ; 0.001 ; 0.020 REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 1 REMARK 3 REMARK 3 TLS GROUP : 1 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : A 11 A 223 REMARK 3 ORIGIN FOR THE GROUP (A): 11.9108 -0.1492 13.0807 REMARK 3 T TENSOR REMARK 3 T11: 0.3203 T22: 0.3396 REMARK 3 T33: 0.2397 T12: -0.0274 REMARK 3 T13: -0.0055 T23: -0.0110 REMARK 3 L TENSOR REMARK 3 L11: 0.7743 L22: 3.5502 REMARK 3 L33: 0.8779 L12: 0.1036 REMARK 3 L13: -0.0031 L23: -0.1537 REMARK 3 S TENSOR REMARK 3 S11: 0.0044 S12: -0.0331 S13: -0.0174 REMARK 3 S21: 0.1639 S22: 0.0210 S23: 0.0939 REMARK 3 S31: -0.0894 S32: -0.0055 S33: -0.0254 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : BABINET MODEL WITH MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE REMARK 3 RIDING POSITIONS. REMARK 4 REMARK 4 2XHX COMPLIES WITH FORMAT V. 3.20, 01-DEC-08 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 21-JUN-10. REMARK 100 THE PDBE ID CODE IS EBI-44322. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : NULL REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.54178 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : NULL REMARK 200 DETECTOR MANUFACTURER : NULL REMARK 200 INTENSITY-INTEGRATION SOFTWARE : NULL REMARK 200 DATA SCALING SOFTWARE : NULL REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 4767 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.80 REMARK 200 RESOLUTION RANGE LOW (A) : 37.48 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.0 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 96.1 REMARK 200 DATA REDUNDANCY : 2.4 REMARK 200 R MERGE (I) : 0.15 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : NULL REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: OTHER REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NONE REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 34.89 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 1.90 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 20.59100 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A -12 REMARK 465 GLY A -11 REMARK 465 SER A -10 REMARK 465 SER A -9 REMARK 465 HIS A -8 REMARK 465 HIS A -7 REMARK 465 HIS A -6 REMARK 465 HIS A -5 REMARK 465 HIS A -4 REMARK 465 HIS A -3 REMARK 465 SER A -2 REMARK 465 SER A -1 REMARK 465 GLY A 0 REMARK 465 LEU A 1 REMARK 465 VAL A 2 REMARK 465 PRO A 3 REMARK 465 ARG A 4 REMARK 465 GLY A 5 REMARK 465 SER A 6 REMARK 465 HIS A 7 REMARK 465 MET A 8 REMARK 465 ASP A 9 REMARK 465 GLN A 10 REMARK 465 GLU A 225 REMARK 465 ARG A 226 REMARK 465 ASP A 227 REMARK 465 LYS A 228 REMARK 465 GLU A 229 REMARK 465 VAL A 230 REMARK 465 SER A 231 REMARK 465 ASP A 232 REMARK 465 ASP A 233 REMARK 465 GLU A 234 REMARK 465 ALA A 235 REMARK 465 GLU A 236 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LYS A 224 CA C O CB CG CD CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O GLN A 23 N GLU A 25 2.20 REMARK 500 OE2 GLU A 158 OH TYR A 160 2.16 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ALA A 24 -63.92 44.54 REMARK 500 ASN A 40 40.03 71.09 REMARK 500 GLU A 42 5.45 -56.22 REMARK 500 THR A 65 -48.01 -131.46 REMARK 500 LYS A 74 -67.35 80.69 REMARK 500 LEU A 107 65.95 -115.04 REMARK 500 VAL A 148 116.32 -162.14 REMARK 500 ALA A 166 -134.53 52.80 REMARK 500 SER A 211 51.61 -149.12 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE T5M A1224 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1UY9 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-BENZO[1,3] REMARK 900 DIOXOL-,5-YLMETHYL-9-BUTYL-9H-PURIN-6- REMARK 900 YLAMINE REMARK 900 RELATED ID: 2CDD RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 4-(4-(2,3-DIHYDRO- REMARK 900 BENZOL(1,4)DIOXIN-6-YL)-5-METHYL-1H- REMARK 900 PYRAZOL-3-YL)-6-ETHYL-BENZENE-1,3-DIOL REMARK 900 RELATED ID: 1YES RELATED DB: PDB REMARK 900 HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "OPEN REMARK 900 " CONFORMATION REMARK 900 RELATED ID: 1BYQ RELATED DB: PDB REMARK 900 HSP90 N-TERMINAL DOMAIN BOUND TO ADP-MG REMARK 900 RELATED ID: 2BSM RELATED DB: PDB REMARK 900 NOVEL, POTENT SMALL MOLECULE INHIBITORS OF REMARK 900 THE MOLECULAR CHAPERONE HSP90 DISCOVERED REMARK 900 THROUGH STRUCTURE-BASED DESIGN REMARK 900 RELATED ID: 1OSF RELATED DB: PDB REMARK 900 HUMAN HSP90 IN COMPLEX WITH 17-DESMETHOXY- REMARK 900 17-N,N-DIMETHYLAMINOETHYLAMINO-GELDANAMYCIN REMARK 900 RELATED ID: 2WI3 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE REMARK 900 INHIBITORS OF THE HSP90 CHAPERONE REMARK 900 RELATED ID: 1UY8 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3- REMARK 900 TRIMETHOXY-BENZYL)-9H-PURIN-6YLAMINE REMARK 900 RELATED ID: 2WI4 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE REMARK 900 INHIBITORS OF THE HSP90 CHAPERONE REMARK 900 RELATED ID: 2BUG RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE TPR DOMAIN FROM REMARK 900 PROTEIN PHOSPHATASE 5 IN COMPLEX WITH HSP90 REMARK 900 DERIVED PEPTIDE REMARK 900 RELATED ID: 2UWD RELATED DB: PDB REMARK 900 INHIBITION OF THE HSP90 MOLECULAR CHAPERONE REMARK 900 IN VITRO AND IN VIVO BY NOVEL, SYNTHETIC REMARK 900 , POTENT RESORCINYLIC PYRAZOLE, ISOXAZOLE AMIDE REMARK 900 ANALOGS REMARK 900 RELATED ID: 2WI7 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE REMARK 900 INHIBITORS OF THE HSP90 CHAPERONE REMARK 900 RELATED ID: 2BT0 RELATED DB: PDB REMARK 900 NOVEL, POTENT SMALL MOLECULE INHIBITORS OF REMARK 900 THE MOLECULAR CHAPERONE HSP90 DISCOVERED REMARK 900 THROUGH STRUCTURE-BASED DESIGN REMARK 900 RELATED ID: 1YER RELATED DB: PDB REMARK 900 HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, " REMARK 900 CLOSED" CONFORMATION REMARK 900 RELATED ID: 2XDU RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE REMARK 900 INHIBITOR BOUND REMARK 900 RELATED ID: 1UYG RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY- REMARK 900 BENZYL)-2-FLUORO-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 2BZ5 RELATED DB: PDB REMARK 900 STRUCTURE-BASED DISCOVERY OF A NEW CLASS REMARK 900 OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2CCU RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 4-CHLORO-6-(4-(4-(4- REMARK 900 METHANESULPHONYL-BENZYL)-PIERAZIN-1-YL)-1H- REMARK 900 PYRAZOL-3-YL)-BENZENE-1,3-DIOL REMARK 900 RELATED ID: 2XDS RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE REMARK 900 INHIBITOR BOUND REMARK 900 RELATED ID: 2XDX RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE REMARK 900 INHIBITOR BOUND REMARK 900 RELATED ID: 2CCS RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 4-CHLORO-6-(4-PIPERAZIN- REMARK 900 1-YL-1H-PYRAZOL-3-YL)-BENZENE-1,2-DIOL REMARK 900 RELATED ID: 1YC3 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA REMARK 900 COMPLEXED WITHDIHYDROXYPHENYLPYRAZOLES REMARK 900 RELATED ID: 1UYF RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4, REMARK 900 5-TRIMETHOXY-BENZYL)-2-FLUORO-9-PENT-4- REMARK 900 YLNYL-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYI RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY- REMARK 900 BENZYL)-2-FLUORO-9-PENT-9H-PURIN-6- REMARK 900 YLAMINE REMARK 900 RELATED ID: 1UYD RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2- REMARK 900 CHLORO-3,4,5-TRIMETHOXY-BENZYL)-9H-PURIN- REMARK 900 6-YLAMINE REMARK 900 RELATED ID: 2BYI RELATED DB: PDB REMARK 900 3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE- REMARK 900 4-CARBOXAMIDES AS INHIBITORS OF THE HSP90 REMARK 900 MOLECULAR CHAPERONE REMARK 900 RELATED ID: 2XDL RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE REMARK 900 INHIBITOR BOUND REMARK 900 RELATED ID: 2WI2 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE REMARK 900 INHIBITORS OF THE HSP90 CHAPERONE REMARK 900 RELATED ID: 1UY6 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3,4, REMARK 900 5-TRIMETHOXY-BENZYL)-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 2VCI RELATED DB: PDB REMARK 900 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE REMARK 900 INHIBITORS: POTENTIAL THERAPEUTIC AGENTS FOR REMARK 900 THE TREATMENT OF CANCER REMARK 900 RELATED ID: 2WI1 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE REMARK 900 INHIBITORS OF THE HSP90 CHAPERONE REMARK 900 RELATED ID: 2VCJ RELATED DB: PDB REMARK 900 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE REMARK 900 INHIBITORS: POTENTIAL THERAPEUTIC AGENTS FOR REMARK 900 THE TREATMENT OF CANCER REMARK 900 RELATED ID: 1YC4 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA REMARK 900 COMPLEXED WITHDIHYDROXYPHENYLPYRAZOLES REMARK 900 RELATED ID: 2XDK RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE REMARK 900 INHIBITOR BOUND REMARK 900 RELATED ID: 2FWZ RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO REMARK 900 THE POTENT WATERSOLUBLE INHIBITOR PU-H71 REMARK 900 RELATED ID: 2C2L RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE CHIP U-BOX E3 REMARK 900 UBIQUITIN LIGASE REMARK 900 RELATED ID: 1UYH RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5- REMARK 900 DIMETHOXY-BENZYL)-2-FLUORO-9H-PURIN-6- REMARK 900 YLAMINE REMARK 900 RELATED ID: 1UYK RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-BENZO[1,3] REMARK 900 DIOXOL-,5-YLMETHYL-9-BUTYL-2-FLUORO-9H- REMARK 900 PURIN-6-YLAMINE REMARK 900 RELATED ID: 2CCT RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 5-(5-CHLORO-2,4- REMARK 900 DIHYDROXY-PHENYL)-4-PIPERAZIN-1-YL-2H- REMARK 900 PYRAZOLE-3-CARBOXYLIC ACID ETHYLAMIDE REMARK 900 RELATED ID: 2FWY RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO REMARK 900 THE POTENT WATERSOLUBLE INHIBITOR PU-H64 REMARK 900 RELATED ID: 1UYL RELATED DB: PDB REMARK 900 STRUCTURE-ACTIVITY RELATIONSHIPS IN PURINE- REMARK 900 BASED INHIBITOR BINDING TO HSP90 ISOFORMS REMARK 900 RELATED ID: 1UYE RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4, REMARK 900 5-TRIMETHOXY-BENZYL)-9-PENT-4-YLNYL-9H- REMARK 900 PURIN-6-YLAMINE REMARK 900 RELATED ID: 2XAB RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH AN INHIBITOR BOUND REMARK 900 RELATED ID: 2WI6 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE REMARK 900 INHIBITORS OF THE HSP90 CHAPERONE REMARK 900 RELATED ID: 1YC1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURES OF HUMAN HSP90ALPHA REMARK 900 COMPLEXED WITHDIHYDROXYPHENYLPYRAZOLES REMARK 900 RELATED ID: 1UYC RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5- REMARK 900 DIMETHOXY-BENZYL)-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UY7 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(4- REMARK 900 METHOXY-BENZYL)-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 2XHT RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE REMARK 900 INHIBITOR BOUND REMARK 900 RELATED ID: 2XHR RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE REMARK 900 INHIBITOR BOUND REMARK 900 RELATED ID: 1YET RELATED DB: PDB REMARK 900 GELDANAMYCIN BOUND TO THE HSP90 GELDANAMYCIN- REMARK 900 BINDING DOMAIN REMARK 900 RELATED ID: 2JJC RELATED DB: PDB REMARK 900 HSP90 ALPHA ATPASE DOMAIN WITH BOUND SMALL REMARK 900 MOLECULE FRAGMENT REMARK 900 RELATED ID: 2BYH RELATED DB: PDB REMARK 900 3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE- REMARK 900 4-CARBOXAMIDES AS INHIBITORS OF THE HSP90 REMARK 900 MOLECULAR CHAPERONE REMARK 900 RELATED ID: 2WI5 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE REMARK 900 INHIBITORS OF THE HSP90 CHAPERONE DBREF 2XHX A 9 236 UNP P07900 HS90A_HUMAN 9 236 SEQADV 2XHX MET A -12 UNP P07900 EXPRESSION TAG SEQADV 2XHX GLY A -11 UNP P07900 EXPRESSION TAG SEQADV 2XHX SER A -10 UNP P07900 EXPRESSION TAG SEQADV 2XHX SER A -9 UNP P07900 EXPRESSION TAG SEQADV 2XHX HIS A -8 UNP P07900 EXPRESSION TAG SEQADV 2XHX HIS A -7 UNP P07900 EXPRESSION TAG SEQADV 2XHX HIS A -6 UNP P07900 EXPRESSION TAG SEQADV 2XHX HIS A -5 UNP P07900 EXPRESSION TAG SEQADV 2XHX HIS A -4 UNP P07900 EXPRESSION TAG SEQADV 2XHX HIS A -3 UNP P07900 EXPRESSION TAG SEQADV 2XHX SER A -2 UNP P07900 EXPRESSION TAG SEQADV 2XHX SER A -1 UNP P07900 EXPRESSION TAG SEQADV 2XHX GLY A 0 UNP P07900 EXPRESSION TAG SEQADV 2XHX LEU A 1 UNP P07900 EXPRESSION TAG SEQADV 2XHX VAL A 2 UNP P07900 EXPRESSION TAG SEQADV 2XHX PRO A 3 UNP P07900 EXPRESSION TAG SEQADV 2XHX ARG A 4 UNP P07900 EXPRESSION TAG SEQADV 2XHX GLY A 5 UNP P07900 EXPRESSION TAG SEQADV 2XHX SER A 6 UNP P07900 EXPRESSION TAG SEQADV 2XHX HIS A 7 UNP P07900 EXPRESSION TAG SEQADV 2XHX MET A 8 UNP P07900 EXPRESSION TAG SEQADV 2XHX THR A 63 UNP P07900 SER 63 CONFLICT SEQRES 1 A 249 MET GLY SER SER HIS HIS HIS HIS HIS HIS SER SER GLY SEQRES 2 A 249 LEU VAL PRO ARG GLY SER HIS MET ASP GLN PRO MET GLU SEQRES 3 A 249 GLU GLU GLU VAL GLU THR PHE ALA PHE GLN ALA GLU ILE SEQRES 4 A 249 ALA GLN LEU MET SER LEU ILE ILE ASN THR PHE TYR SER SEQRES 5 A 249 ASN LYS GLU ILE PHE LEU ARG GLU LEU ILE SER ASN SER SEQRES 6 A 249 SER ASP ALA LEU ASP LYS ILE ARG TYR GLU THR LEU THR SEQRES 7 A 249 ASP PRO SER LYS LEU ASP SER GLY LYS GLU LEU HIS ILE SEQRES 8 A 249 ASN LEU ILE PRO ASN LYS GLN ASP ARG THR LEU THR ILE SEQRES 9 A 249 VAL ASP THR GLY ILE GLY MET THR LYS ALA ASP LEU ILE SEQRES 10 A 249 ASN ASN LEU GLY THR ILE ALA LYS SER GLY THR LYS ALA SEQRES 11 A 249 PHE MET GLU ALA LEU GLN ALA GLY ALA ASP ILE SER MET SEQRES 12 A 249 ILE GLY GLN PHE GLY VAL GLY PHE TYR SER ALA TYR LEU SEQRES 13 A 249 VAL ALA GLU LYS VAL THR VAL ILE THR LYS HIS ASN ASP SEQRES 14 A 249 ASP GLU GLN TYR ALA TRP GLU SER SER ALA GLY GLY SER SEQRES 15 A 249 PHE THR VAL ARG THR ASP THR GLY GLU PRO MET GLY ARG SEQRES 16 A 249 GLY THR LYS VAL ILE LEU HIS LEU LYS GLU ASP GLN THR SEQRES 17 A 249 GLU TYR LEU GLU GLU ARG ARG ILE LYS GLU ILE VAL LYS SEQRES 18 A 249 LYS HIS SER GLN PHE ILE GLY TYR PRO ILE THR LEU PHE SEQRES 19 A 249 VAL GLU LYS GLU ARG ASP LYS GLU VAL SER ASP ASP GLU SEQRES 20 A 249 ALA GLU HET T5M A1224 43 HETNAM T5M 2-TERT-BUTYL-4-(1,3-DIHYDRO-2H-ISOINDOL-2- HETNAM 2 T5M YLCARBONYL)PHENOL FORMUL 2 T5M C19 H21 N O2 FORMUL 3 HOH *69(H2 O) HELIX 1 1 ALA A 24 ASN A 35 1 12 HELIX 2 2 ASN A 40 GLU A 42 5 3 HELIX 3 3 ILE A 43 THR A 63 1 21 HELIX 4 4 THR A 99 LEU A 107 1 9 HELIX 5 5 GLY A 114 ALA A 124 1 11 HELIX 6 6 SER A 129 PHE A 134 1 6 HELIX 7 7 GLY A 137 LEU A 143 5 7 HELIX 8 8 THR A 195 LEU A 198 5 4 HELIX 9 9 GLU A 199 SER A 211 1 13 SHEET 1 AA 8 VAL A 17 ALA A 21 0 SHEET 2 AA 8 SER A 169 ARG A 173 -1 O PHE A 170 N PHE A 20 SHEET 3 AA 8 TYR A 160 SER A 164 -1 O ALA A 161 N ARG A 173 SHEET 4 AA 8 ALA A 145 THR A 152 -1 O VAL A 148 N SER A 164 SHEET 5 AA 8 LYS A 185 LEU A 190 -1 O LYS A 185 N ILE A 151 SHEET 6 AA 8 THR A 88 ASP A 93 -1 O LEU A 89 N LEU A 188 SHEET 7 AA 8 ILE A 78 ASN A 83 -1 O ASN A 79 N VAL A 92 SHEET 8 AA 8 ILE A 218 LEU A 220 1 O THR A 219 N LEU A 80 SITE 1 AC1 12 LEU A 48 ASN A 51 SER A 52 ASP A 54 SITE 2 AC1 12 ALA A 55 ASP A 93 ILE A 96 GLY A 97 SITE 3 AC1 12 MET A 98 PHE A 138 THR A 184 VAL A 186 CRYST1 47.231 41.182 49.827 90.00 101.28 90.00 P 1 21 1 2 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.021173 0.000000 0.004223 0.00000 SCALE2 0.000000 0.024282 0.000000 0.00000 SCALE3 0.000000 0.000000 0.020465 0.00000